Company intelligence / Profile preview

Aneira Pharma

San Diego, California, United Statesaneirapharma.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Aneira Pharma is developing ANR-001.1, a novel topical formulation for hair growth that has shown promising results in promoting thicker, darker hair growth in both men and women. The company has two clinical trials: a Phase 1 study of safety and pharmacokinetics in male subjects with androgenetic alopecia, and an Early Phase 1 study evaluating the safety and efficacy of a Latanoprost/Minoxidil formulation for eyebrow hypotrichosis[2][5].

Therapeutic areas: Dermatology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

ANR-001

Pre-clinical

Indications: Androgenetic alopecia

Beyond the preview

Go deeper on Aneira Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aneira Pharma.

Explore the full profile